摘要
随机、对照、开放性临床试验评价硫酸爱大霉素治疗呼吸道及泌尿道细菌感染性疾病的临床有效性和安全性。硫酸爱大霉素为水针剂与粉针剂，选用奈替米星作对照。水针剂试验组与对照组各３０例，开放试验４０例。粉针剂试验组２１例，对照组２２例。给药方法两药均为１００ｍｇ／次，２次／ｄ，疗程７－１０ｄ。结果：水针剂：试验组与对照组临床有效率均为９０．０％，细菌清除率分别为８６．２％与８０％，药物不良反应发生率均为１０．０％。开放试验有效率、细菌清除率和药物不良反应发生率分别是８７．５％，７５．６％与１０．０％。粉针剂试验结果与水针剂近似。
The purpose of the study is to evaluate the clinical efficacy and safety of etimicin on the treatment of bacterial infections in respiratory and urinary tracts. 143 patients were involved in the prospective randomized-controlled and open clinical trial. There were two formulations of etimicin, i.e. etimicin in solution and etimicin in powder. In the randomized-controlled study 30 patients were treated with etimicin in solution or netimicin, respectively. In addition, in the open study there were 40 patients only treated with etimicin in solution. When etimicin in powder was used, 21 patients were treated with etimicin and 22 patients were treated with netimicin. Etimicin and netimicin were administered twice a day for 7-10 days, at a daily dose of 200 mg. The clinical efficacy rates of etimicin in solution and netimicin were both 90.0%, and the bacterial clearance rates were 86.2% and 80.0%, respectively. The adverse reactions were both 10.0% respectively. The clinical efficacy rate, bacterial clearance rate and adverse reactions rate in open clinical trial were 87.5%, 75.6% and 10.0%, respectively. The results of etimicin in powder were similar to those obtained from etimicin in solution. Etimicin sulfate is a new effective and safe antibiotics of aminoglycosides.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1998年第2期65-69,共5页
The Chinese Journal of Clinical Pharmacology
